Evidence map›Paper›PMID 42117906›Full record

ArticleActa crystallographica. Section D, Structural biology2026

Structural basis for high-affinity inhibitor binding to lipid kinases PIP4K2A and PIP4K2B.

Zunyu He, Song Chen, Fabrizio Micheli, Agostino Cianciulli, Claudia Beato, Jonathan Ellman, Ya Ha

Abstract read
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zunyu HeDepartment of Pharmacology, Yale School of Medicine, New Haven, CT 06520, USA.
Song ChenDepartment of Pharmacology, Yale School of Medicine, New Haven, CT 06520, USA.
Fabrizio MicheliAptuit Srl, an Evotec Company, Via Fleming 4, 37135 Verona, Italy.ORCID 0000-0002-1871-5288
Agostino CianciulliAptuit Srl, an Evotec Company, Via Fleming 4, 37135 Verona, Italy.
Claudia BeatoDepartment of Chemistry, Yale University, New Haven, CT 06520, USA.
Jonathan EllmanDepartment of Pharmacology, Yale School of Medicine, New Haven, CT 06520, USA.
Ya HaDepartment of Pharmacology, Yale School of Medicine, New Haven, CT 06520, USA.

Funding

Next-generation C-H functionalization methods for organic synthesis and their applications to biological inquiryR35GM122473 · NIGMS · YALE UNIVERSITY · PI JONATHAN A ELLMAN · 2017 to 2026
$7.6M
The biochemical mechanism and pharmacological inhibition of phosphatidylinositol phosphate kinasesR01GM150502 · NIGMS · YALE UNIVERSITY · PI YA HA · 2023 to 2026
$1.4M
National Institutes of Health, National Institute of General Medical Sciences GM122473National Institutes of Health, National Institute of General Medical Sciences GM138722National Institutes of Health, National Institute of General Medical Sciences GM150502NIGMS NIH HHS R01 GM150502NIGMS NIH HHS R35 GM122473
6 · The paper itself

Abstract

The phosphatidylinositol 5-phosphate 4-kinases (PIP4Ks) are an evolutionarily conserved family of lipid kinases that phosphorylate phosphatidylinositol 5-phosphate to generate phosphatidylinositol 4,5-bisphosphate. In mammals, the catalytically active α and β isoforms, encoded by PIP4K2A and PIP4K2B, respectively, localize to distinct cellular compartments and have been implicated in metabolism, immune regulation and tumorigenesis, prompting interest in their pharmacological inhibition. Notably, most reported small-molecule inhibitors display substantially higher potency towards the α isoform than the β isoform, suggesting intrinsic structural features that limit the effective targeting of PIP4K2B. Here, we report the crystal structure of PIP4K2A in complex with 422A, a potent dual α/β inhibitor with improved metabolic stability. The structure reveals an unexpected, water-mediated interaction in which a pyridyl nitrogen of the inhibitor engages a conserved structured water molecule in the roof of the specificity pocket, constraining the orientation of the pyridylmethyl side chain and stabilizing a rigid, high-affinity binding mode. Comparative structural analysis with the PIP4K2A-selective inhibitor BAY-091 shows that deeper penetration into the specificity pocket enhances PIP4K2A binding but is accompanied by local steric constraints that are likely to be less well tolerated in PIP4K2B. Together, these findings define structural determinants of isoform-dependent inhibitor binding within the PIP4K family and provide a framework for structure-guided optimization of lipid kinase inhibitors with improved isoform balance.

Indexed as

Enzyme InhibitorsPhosphotransferases (Alcohol Group Acceptor)Protein Kinase InhibitorsBinding SitesCrystallography, X-RayHumansModels, MolecularProtein BindingEnzyme InhibitorsPhosphotransferases (Alcohol Group Acceptor)PIP4K2A protein, humanProtein Kinase Inhibitorsinhibitorslipid kinasesPIP4Kselectivitystructured water

Identifiers

PMID42117906
PMCPMC13224930

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.